What's New

MVP to host Roundtable Panel and Open House for AASV members

Announcement

MVP Laboratories teams up with Dr. Susan Detmer to spread influenza awareness

In an effort to keep our clients aware of the latest developments, MVP Laboratories is working with Dr. Susan Detmer of the University of Minnesota to publish an informative newsletter entitled Flu News. It deals with SIV as well as the current H1N1 pandemic and its implications for both humans and swine.

Susan Detmer received her doctor of veterinary medicine at the University of Minnesota, College of Veterinary Medicine in St. Paul, MN in 2003. In 2006, Susan began her combined PhD/residency training in anatomic pathology at the University of Minnesota. Her field of research is in control and characterization of swine influenza viruses, in particular the molecular epidemiology of swine influenza viruses of perceived high virulence. She is currently working with the Minnesota Center for Excellence for Influenza Research & Surveillance (MCEIRS) under her research advisors, Drs. Marie Gramer and Sagar Goyal.

CLICK HERE to view issues of Flu News.

MVP Laboratories partners with MJ Biologics to combat PRRSV

MVP Laboratories and MJ Biologics have successfully collaborated to produce a USDA licensed autogenous MJPRRS vaccine that can help swine producers tackle the complex PRRSV disease problem.

MJPRRS™ Viral Antigen Concentrate Vaccine Technology and MJPRRS™ Grouping Technology are combined with MVP's proprietary EMULSIGEN®-D adjuvant to produce the second generation MJPRRS™ Vaccine. This vaccine contains the maximum concentrations of PRRS viral antigens in the presence of MVP's extraordinary adjuvant.  

The two companies have been working on scale-up of MJ Biologics' unique technology in MVP's new production facility in Omaha, NE.  MJPRRS vaccines produced by MVP Laboratories must pass stringent quality control testing prior to release to assure the presence of optimal levels of antigenic mass.  At this time, MVP reports that it is able to produce the unique vaccine in 100,000 dose serials.